Treovir

Treovir Announces Opening of G207 Phase 2 Clinical Trial in Children with Recurrent Brain Tumors

4 December 2024 -- Alabama, US -- Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in pediatric brain tumor patients. G207 is being evaluated for efficacy in a single-arm Phase 2 study of 30 pediatric patients with high grade gliomas at first recurrence, a uniformly fatal...